BackAvadel Pharmaceuticals plc Overview

Avadel Pharmaceuticals plc Other Current Liabilities

Latest other current liabilities for AVDL: $49M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$49.17M
44.01% YoYΔ $15.03M vs prior year quarter

Peer trimmed avg / median

Loading

Avadel Pharmaceuticals plc Other Current Liabilities History

Loading

Avadel Pharmaceuticals plc vs. peers: Other Current Liabilities Comparison

Loading

Avadel Pharmaceuticals plc Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Avadel Pharmaceuticals plc (AVDL) FAQ

As of the most recent data (September 2025), AVDL shows a other current liabilities of $49M. That compares with $34M in the prior-year period — up 44.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AVDL's other current liabilities is now $49M (was $34M) — a 44.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Avadel Pharmaceuticals plc is outperforming or lagging.

Tracking AVDL's other current liabilities over time shows whether Avadel Pharmaceuticals plc is scaling, shrinking, or reshaping that part of the business. The current reading is $49M That compares with $34M in the prior-year period — up 44.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Avadel Pharmaceuticals plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $49M) with ownership activity and broader fundamentals.

Avadel Pharmaceuticals plc's other current liabilities is $49M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.